Early Antiangiogenic Activity of Bevacizumab Evaluated by Computed Tomography Perfusion Scan in Patients with Advanced Hepatocellular Carcinoma

Abstract

Background. Hepatocellular carcinoma (HCC) is a highly vascularized tumor with a poor prognosis. In a phase II study that combined bevacizumab with gemcitabine and oxaliplatin in advanced HCC, we examined computed tomography perfusion (CTp) scan parameters as surrogate markers of angiogenesis after bevacizumab administration.Methods. HCC patients received bevacizumab alone i.v. at 10 mg/kg on day 1 during cycle 1. CTp scanning was performed at baseline and days 10 -12 to assess changes in tissue blood flow (BF), blood volume (BV), mean transit time (MTT), and permeability surface area product (PS).Results. Compared with baseline, a significant de-

Quantitative evaluation of viable tissue perfusion changes with contrast-enhanced greyscale ultrasound in a mouse hepatoma model following treatment with different doses of thalidomide

“…In light of the generally accepted importance of angiogenesis for tumour growth and progression and the increasing number of anti-angiogenic therapy protocols, other imaging strategies including contrastenhanced MRI and contrast-enhanced CT have been used to evaluate cancer-induced angiogenesis and the anti-angiogenic therapeutic effect. However, mixed results in MTT changes were found between our study and previous studies using contrast-enhanced CT [18]. Studies using contrast-enhanced CT found that tumour treatment with anti-angiogenic agents induced a significant increase in MTT; however, our study found that there was no significant difference in MTT between treated tumours and control tumours.…”

Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis

“…The partial recanalization of the portal venous system corroborates the hypothesis that sorafenib has a direct action on tumor cells invading the portal system and a modulation effect on the production of pro-thrombotic cytokines by the neoplastic cells (18,30). From the imaging point of view, as also described by other authors (31,32), in the present study a marked response to treatment in a highly enhancing lesion was observed. Such a response can be defined in terms of nodule devascularization (D% art reduction from 120 to 30/24% in our case), diameter stability, and, in a small number of cases, consistent volume decrease (maximum diameter reduction from 12 to 7 cm).…”

Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib

“…In our study, perfusion CT scans also showed an early reduction in blood flow to the tumor site after 1 month of treatment with sunitinib, indicative of direct and rapid effects on tumor vasculature. Similarly, in a phase II study using bevacizumab, Zhu and colleagues reported a significant decrease in tumor perfusion parameters including blood flow and blood volume within 2 weeks after bevacizumab administration in patients with advanced HCC (25).…”